CompletedNCT05560009

An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

Studying Soft tissue sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Mayo Clinic
Principal Investigator
Deanna Hasenauer, Ph.D.
Mayo Clinic
Intervention
Fluorodopa F 18(drug)
Enrollment
9 target
Eligibility
18 years · All sexes
Timeline
2022 – 2024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05560009 on ClinicalTrials.gov

Other trials for Soft tissue sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Soft tissue sarcoma →

← Back to all trials